Literature DB >> 30501965

New approaches for the treatment of Alzheimer's disease.

Paul V Fish1, David Steadman2, Elliott D Bayle3, Paul Whiting4.   

Abstract

Alzheimer's disease (AD) is the most prevalent chronic neurodegenerative disease. Current approved therapies are symptomatic treatments having some effect on cognitive function. Therapies that target β-amyloid (Aβ) have been the focus of efforts to develop a disease modification treatment for AD but these approaches have failed to show any clinical benefit so far. Beyond the 'Aβ hypothesis', there are a number of newer approaches to treat AD with neuroinflammation emerging as a very active area of research based on risk gene analysis. This short review will summarize approved drug therapies, recent clinical trials and new approaches for the treatment of AD.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Disease modification; Drug discovery pipeline; Neurodegeneration; Neuroinflammation; Symptomatic treatments

Mesh:

Substances:

Year:  2018        PMID: 30501965     DOI: 10.1016/j.bmcl.2018.11.034

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  30 in total

Review 1.  Mitochondrial dynamics and transport in Alzheimer's disease.

Authors:  Padraig J Flannery; Eugenia Trushina
Journal:  Mol Cell Neurosci       Date:  2019-06-16       Impact factor: 4.314

Review 2.  The amyloid precursor protein: a converging point in Alzheimer's disease.

Authors:  Alexandré Delport; Raymond Hewer
Journal:  Mol Neurobiol       Date:  2022-05-17       Impact factor: 5.590

3.  Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions.

Authors:  Byung Woo Kang; Fred Kim; Joon-Yong Cho; SangYun Kim; Jinseol Rhee; Jai Jun Choung
Journal:  Alzheimers Res Ther       Date:  2022-07-08       Impact factor: 8.823

Review 4.  Modeling Neurodegenerative Diseases Using In Vitro Compartmentalized Microfluidic Devices.

Authors:  Louise Miny; Benoît G C Maisonneuve; Isabelle Quadrio; Thibault Honegger
Journal:  Front Bioeng Biotechnol       Date:  2022-06-24

Review 5.  Current and emerging therapeutic targets of alzheimer's disease for the design of multi-target directed ligands.

Authors:  Laura Blaikie; Graeme Kay; Paul Kong Thoo Lin
Journal:  Medchemcomm       Date:  2019-10-16       Impact factor: 3.597

6.  The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route.

Authors:  Yueyao Jiang; Chenqi Liu; Wanchen Zhai; Ning Zhuang; Tengfei Han; Zhiying Ding
Journal:  Int J Nanomedicine       Date:  2019-11-27

7.  Antioxidant, antimicrobial and neuroprotective effects of Octaviania asterosperma in vitro.

Authors:  Mustafa Sevindik; Hasan Akgul; Zeliha Selamoglu; Nady Braidy
Journal:  Mycology       Date:  2020-12-02

Review 8.  Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.

Authors:  Priscila Baltazar Gonçalves; Ana Carolina Rennó Sodero; Yraima Cordeiro
Journal:  Biomolecules       Date:  2021-05-20

9.  GPS driving: a digital biomarker for preclinical Alzheimer disease.

Authors:  Sayeh Bayat; Ganesh M Babulal; Suzanne E Schindler; Anne M Fagan; John C Morris; Alex Mihailidis; Catherine M Roe
Journal:  Alzheimers Res Ther       Date:  2021-06-14       Impact factor: 6.982

Review 10.  Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease.

Authors:  Teeba Athar; K Al Balushi; Shah Alam Khan
Journal:  Mol Biol Rep       Date:  2021-06-28       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.